Jean-Claude Tardif

This inventor holds 16 USPTO granted patents and 16 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Hoffmann-La Roche Inc., Institut De Cardiologie De Montreal, 9494-1861 Québec Inc.. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Claude Tardif. Retrieved from https://idiyas.com/inventor/jean-claude-tardif

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 16)

% Patents Active = 81.3

CIPO Patents = 2 (Patent Applications = 13)

EPO Patents = 3 (Patent Applications = 16)

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 34(Granted Patents)

Location History:

Laval, CA (2001 - 2023)
Montreal, CA (2018 - 2023)

Company Filing History:

6 out of 5,026

Hoffmann-La Roche Inc.

patents

6 out of 16

Institut De Cardiologie De Montreal

patents

2 out of 2

9494-1861 Québec Inc.

patents

4. 1 out of 4

Montreal Heart Institute

patents

5. 1 out of 1

Quatro Scientific, Inc.

patent

Years Active: 2001-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. D1150869 - Cabinet pill dispenser (2026-10-06),

2. 12514832 - Methods for using low-dose colchicine after myocardial infarction (2026-01-06),

3. 12371748 - Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent (2025-07-29),

4. D1083357 - Cabinet pill dispenser (2025-07-15),

5. 11844771 - Methods of treating acute respiratory distress syndrome using colchicine (2023-12-19),

6. 11840707 - Co-culture system and method for in vitro assessment of reverse cholesterol transport (2023-12-12),

7. 11549142 - CETP inhibitors for therapeutic use (2023-01-10),

8. 11401554 - Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent (2022-08-02),

9. 11400063 - Early administration of low-dose colchicine after myocardial infarction (2022-08-02),

10. 10711303 - CETP inhibitors for therapeutic use (2020-07-14),

11. 10584385 - Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent (2020-03-10),

12. 9909178 - Dalcetrapib for therapeutic use (2018-03-06),

13. 8163699 - Method for the treatment of valvular disease (2012-04-24),

14. 8030010 - Method for detecting a biomarker of oxidative stress in a biological sample (2011-10-04),

15. 7993859 - Method for quantifying oxidative stress caused by different biological pathways (2011-08-09),

Title: Jean-Claude Tardif: A Pioneer in Medical Innovations

Introduction

Jean-Claude Tardif is a renowned inventor based in Montreal, Canada, known for his significant contributions to the field of medicine. With a commendable portfolio of 12 patents, Tardif continues to advance healthcare through innovative solutions aimed at addressing critical medical challenges.

Latest Patents

Among his latest inventions, Tardif has developed methods for treating Acute Respiratory Distress Syndrome using colchicine. This patent discloses methods for administering colchicine to patients in need, showcasing Tardif's commitment to improving patient outcomes during critical health crises. Another noteworthy patent involves a co-culture system and method for in vitro assessment of reverse cholesterol transport. This invention provides a system that mimics in vivo cholesterol efflux and uptake, allowing for the evaluation of pharmacological agents' effects on cellular processes or for diagnostic purposes.

Career Highlights

Tardif's career is marked by his association with prestigious organizations such as the Institut De Cardiologie De Montreal and Hoffmann-La Roche Inc. His experience in these institutions has significantly influenced his research and development efforts, focusing on cardiovascular health and pharmaceutical advancements.

Collaborations

Throughout his career, Tardif has collaborated with notable professionals, including Marie-Pierre Dube and Eric Joseph Niesor. These collaborations have fostered an environment of innovation, contributing to the successful development of his patented technologies.

Conclusion

Jean-Claude Tardif exemplifies the spirit of innovation in the medical field. Through his patents and collaborative efforts, he continues to play a vital role in advancing health technologies that have the potential to improve patient care and outcomes in critical medical situations.

Profile summary based on public USPTO records.